Ratings Abbott India Limited NSE India S.E.

Equities

Market Closed - NSE India S.E. Other stock markets 07:43:50 2024-05-15 EDT			5-day change	1st Jan Change
26,411 ^INR	-1.37%		+1.83%	+15.58%

05-10	Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3%	MT
05-09	Drugmaker Abbott India posts Q4 profit rise on higher sales	RE

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

With an expected P/E ratio at 47.1 and 42.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.

	1st Jan change	Capi.	ESG Refinitiv
ABBOTT INDIA LIMITED	+15.58%	6.82B	-
NOVO NORDISK A/S	+31.37%	588B	B
JOHNSON & JOHNSON	-2.60%	364B	C+
MERCK & CO., INC.	+20.83%	326B	B-
ABBVIE INC.	+5.69%	285B	C+
ASTRAZENECA PLC	+14.83%	239B	B+
NOVARTIS AG	+9.93%	210B	B-
ROCHE HOLDING AG	-6.95%	200B	A+
AMGEN INC.	+10.77%	167B	C+
PFIZER, INC.	+0.10%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality